Clinical Trial: To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3)

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07620366) titled 'To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3)' on May 27.

Brief Summary: This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial to evaluate efficacy and safety of QL2401 in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis (F2-F3).

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Metabolic Dysfunction-associated Steatohepatitis (MASH)

Intervention: DRUG: QL2401 25 mg

QL2401 is a recombinant fusion protein administered via subcutaneo...